Development of novel diagnostic system for pancreatic cancer, including early stages, measuring mRNA of whole blood cells.
Aged
Biomarkers, Tumor
Blood Cells
/ metabolism
Computational Biology
/ methods
Early Detection of Cancer
/ methods
Female
Gene Expression Profiling
/ methods
Humans
Male
Middle Aged
Molecular Sequence Annotation
Neoplasm Staging
Pancreatic Neoplasms
/ diagnosis
RNA, Messenger
/ genetics
Reproducibility of Results
Risk Factors
Sensitivity and Specificity
Pancreatic Neoplasms
clinical trial
in vitro diagnostics
mRNA screening system
pancreas cancer
whole blood cells
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
24
10
2018
revised:
01
02
2019
accepted:
07
02
2019
pubmed:
12
2
2019
medline:
17
4
2019
entrez:
12
2
2019
Statut:
ppublish
Résumé
Pancreatic ductal adenocarcinoma (PDAC) is the most life-threating disease among all digestive system malignancies. We developed a blood mRNA PDAC screening system using real-time detection PCR to detect the expression of 56 genes, to discriminate PDAC from noncancer subjects. We undertook a clinical study to assess the performance of the developed system. We collected whole blood RNA from 53 PDAC patients, 102 noncancer subjects, 22 patients with chronic pancreatitis, and 23 patients with intraductal papillary mucinous neoplasms in a per protocol analysis. The sensitivity of the system for PDAC diagnosis was 73.6% (95% confidence interval, 59.7%-84.7%). The specificity for noncancer volunteers, chronic pancreatitis, and patients with intraductal papillary mucinous neoplasms was 64.7% (54.6%-73.9%), 63.6% (40.7%-82.8%), and 47.8% (26.8%-69.4%), respectively. Importantly, the sensitivity of this system for both stage I and stage II PDAC was 78.6% (57.1%-100%), suggesting that detection of PDAC by the system is not dependent on the stage of PDAC. These results indicated that the screening system, relying on assessment of changes in mRNA expression in blood cells, is a viable alternative screening strategy for PDAC.
Identifiants
pubmed: 30742728
doi: 10.1111/cas.13971
pmc: PMC6447845
doi:
Substances chimiques
Biomarkers, Tumor
0
RNA, Messenger
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1364-1388Subventions
Organisme : KUBIX Inc.
Organisme : Japan Ministry of Health, Labour, and Welfare
Organisme : Japan Agency for Medical Research and Development
Organisme : Kanazawa University Hospital
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
Clin Cancer Res. 2009 Mar 15;15(6):1907-14
pubmed: 19276278
Lancet. 2016 Jul 2;388(10039):73-85
pubmed: 26830752
Cancer. 1990 Apr 1;65(7):1557-61
pubmed: 2311067
Semin Cell Dev Biol. 2017 Jul;67:39-47
pubmed: 28267596
Cancer Sci. 2017 Nov;108(11):2122-2129
pubmed: 28898495
Cancer Res. 2008 Dec 15;68(24):10267-79
pubmed: 19074895
Hepatogastroenterology. 1991 Apr;38(2):143-8
pubmed: 1855772
Jpn J Clin Oncol. 2011 Jan;41(1):40-51
pubmed: 20819833
Biochem Biophys Res Commun. 2010 Sep 10;400(1):7-15
pubmed: 20682290
J Am Coll Surg. 2007 Oct;205(4 Suppl):S81-6
pubmed: 17916525
Gastroenterology. 2013 Jun;144(6):1316-26
pubmed: 23622141
Cancer Sci. 2019 Apr;110(4):1364-1388
pubmed: 30742728
Br J Cancer. 1994 Sep;70(3):481-6
pubmed: 8080734
Int J Cancer. 1987 Apr 15;39(4):477-81
pubmed: 3470260
Lancet Oncol. 2005 Jun;6(6):369-76
pubmed: 15925814
Onco Targets Ther. 2017 Sep 15;10:4591-4598
pubmed: 28979147
Pancreatology. 2018 Jan;18(1):61-67
pubmed: 29170051
Gastroenterol Hepatol (N Y). 2017 May;13(5):268-275
pubmed: 28656024
Somatic Cell Genet. 1979 Nov;5(6):957-71
pubmed: 94699
J Gastrointest Oncol. 2011 Sep;2(3):168-74
pubmed: 22811847
Lancet. 2011 Aug 13;378(9791):607-20
pubmed: 21620466
Cancer Sci. 2015 Jun;106(6):672-86
pubmed: 25827621